A fresh look at tumor immunosurveillance and immunotherapy

By M. Smyth, D. Godfrey, J. Trapani. Nature Immunology, 2001

808 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6bba347a54a47fad693fea2edf832617e895a48c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy (2005, background): “membrane-bound molecules including transforming growth factor b (TGF-b), interleukin (IL)–10, prostaglandin E2, FAS, CTLA-4 ligands, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), and programmed death receptor ligand 1 (PD-L1, also B7H1), have been found to be expressed by tumors a”
Systemic effects of local radiotherapy (2009, positive): “The mechanisms of resistance are multiple and complex and include production of immunosuppressive cytokines, downregulation of antigenic molecules on the cancer cells, recruitment within tumors of immunoregulatory myeloid and lymphoid cells, and dysfunction of dendritic cells (DC) [28, 29].”
Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models (2011, background): “In recent years, evidence has accumulated indicating that the immune system can recognize and eliminate malignant tumors (Parish 2003; Smyth et al. 2001).”
Immune infiltration in human tumors: a prognostic factor that should not be ignored (2010, background): “Furthermore, under the pressure of antitumoral immune activity, selection and outgrowth of variant tumor cells with reduced immunogenicity could occur (Smyth et al., 2001; Dunn et al., 2004, 2006).”
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. (2005, background): “On the other hand, in conditions of suboptimal antigen-presenting cell function such as in tumor-bearing hosts (16), CTLA-4–mediated inhibition of T-cell activation can prevent the development of antitumor T-cell responses.”
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. (2004, background): “Functionally, the host is tolerant toward the tumor (1).”
Apoptosis: A Review of Programmed Cell Death (2007, methodology): “Another method of apoptosis suppression in cancer involves evasion of immune surveillance (Smyth et al., 2001).”
Gammadelta T cells for immune therapy of patients with lymphoid malignancies. (2003, methodology): “1 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 ( 38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75) 2 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 ( 37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)”